265 related articles for article (PubMed ID: 12576523)
1. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
[TBL] [Abstract][Full Text] [Related]
2. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
Tsukamoto K; Maugeais C; Glick JM; Rader DJ
J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
[TBL] [Abstract][Full Text] [Related]
3. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
[TBL] [Abstract][Full Text] [Related]
5. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
[TBL] [Abstract][Full Text] [Related]
8. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice.
Tsukamoto K; Smith P; Glick JM; Rader DJ
J Clin Invest; 1997 Jul; 100(1):107-14. PubMed ID: 9202062
[TBL] [Abstract][Full Text] [Related]
9. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M
J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894
[TBL] [Abstract][Full Text] [Related]
10. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
[TBL] [Abstract][Full Text] [Related]
11. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion.
Kypreos KE; van Dijk KW; van Der Zee A; Havekes LM; Zannis VI
J Biol Chem; 2001 Jun; 276(23):19778-86. PubMed ID: 11279066
[TBL] [Abstract][Full Text] [Related]
12. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.
Gerritsen G; Rensen PC; Kypreos KE; Zannis VI; Havekes LM; Willems van Dijk K
J Lipid Res; 2005 Jul; 46(7):1466-73. PubMed ID: 15863838
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects.
Ikewaki K; Zech LA; Brewer HB; Rader DJ
J Lab Clin Med; 2002 Nov; 140(5):369-74. PubMed ID: 12434139
[TBL] [Abstract][Full Text] [Related]
14. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E isoforms and lipoprotein metabolism.
Phillips MC
IUBMB Life; 2014 Sep; 66(9):616-23. PubMed ID: 25328986
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
[TBL] [Abstract][Full Text] [Related]
18. Effects of polymorphism on the lipid interaction of human apolipoprotein E.
Saito H; Dhanasekaran P; Baldwin F; Weisgraber KH; Phillips MC; Lund-Katz S
J Biol Chem; 2003 Oct; 278(42):40723-9. PubMed ID: 12917433
[TBL] [Abstract][Full Text] [Related]
19. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
